Phase Genomics
PrivateLast Round
Grant
Mar 4, 2024
Total Funding Raised
$21.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Phase Genomics operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Grant round in March 2024.
Phase Genomics is a biotechnology company that develops and sells proximity ligation kits, scientific services, and computational analyses for genomic research.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine
Business Model
B2G
Customer Profile
Services & Consulting, Hardware Sales, Government Contracts, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Phase Genomics Comparables
Compare Phase Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CytoTerra Inc. | 89% | |
| Arima Genomics | 88% | |
| Edenroc Sciences | 84% |
For institutional investors. Book with your work email.
Phase Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 4, 2024 | ||||
| Grant | Aug 7, 2023 | ||||
| Grant | Jun 9, 2022 | ||||
| Grant | Sep 30, 2020 | ||||
| Grant | Jan 8, 2020 | ||||
Grant | Feb 25, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Phase Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| Mount Pleasant Ventures | Series A |
| Pack Ventures | Series A |
| Bill & Melinda Gates Foundation | Grant |
| Washington Research Foundation Capital | Seed |
| Congruent Ventures | Seed |
| Andy Hill Cancer Research Endowment Fund | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 44% MoM, reaching 3.6K.
- Jan 23, 2026
Monthly visitors grew 60% MoM, from 1.9K to 3K.
For institutional investors. Book with your work email.
Phase Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Phase Genomics's valuation, stock price, and market status.
Is Phase Genomics a public or private company?
Phase Genomics is a private company.
What is the current stock price of Phase Genomics?
Phase Genomics is a private company, so its shares have no public market price. Caplight tracks Phase Genomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Phase Genomics worth (valuation)?
Valuation information for Phase Genomics is not publicly available.
Can I buy Phase Genomics stock?
Phase Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Phase Genomics's last funding round?
Phase Genomics's most recent funding round was Grant on March 4, 2024.
Who are the main investors in Phase Genomics?
Key investors in Phase Genomics include National Institute of Allergy and Infectious Diseases, Bill & Melinda Gates Foundation, Washington Research Foundation Capital.
Will Phase Genomics IPO soon?
No public IPO plans have been announced for Phase Genomics.
How can I track Phase Genomics secondary market activity?
Caplight tracks bids, offers, and trades in Phase Genomics's shares on secondary markets.